Med-Tech Innovation January 19, 2024

Quibim, a company using imaging biomarkers for precision medicine, has added a new cancer detection capability to its prostate tool based on AI, QP-Prostate. The updated product, which uses algorithms trained on actual pathology data as ground truth, has been given a CE mark for the European Union and a UKCA mark for the United Kingdom.

As MRI scans have become standard-of-care for prostate cancer, and populations at higher risk of the disease continue to grow, many radiology departments have not had the proper resources in place to handle the avalanche of advanced medical imagery needing to be analysed to appropriately manage prostate cancer patients. QP-prostate, one of Quibim’s flagship products, was developed to overcome this challenge by using AI...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Pharma / Biotech, Precision Medicine, Technology
Putting Patients First by Extending the Reach of World-Class Care
Healthcare's most promising tech
AI In Healthcare: A New Era Of Personalized Patient Care
23andMe reports sales decline a day after announcing plans to cut 40% of workforce
Patient-derived organoids: Transforming cancer research and personalized medicine

Share This Article